DURECT Stock Price, News & Analysis

Welcome to our dedicated page for DURECT news (Ticker: DRRX), a resource for investors and traders seeking the latest updates and insights on DURECT stock.

The DURECT Corporation (DRRX) news feed on Stock Titan aggregates historical company announcements, clinical updates, financial disclosures and transaction-related communications for this former Nasdaq-listed biopharmaceutical issuer. DURECT has described itself as a late-stage biopharmaceutical company focused on epigenetic therapies that target dysregulated DNA methylation, with particular emphasis on serious and life-threatening conditions such as alcohol-associated hepatitis (AH) and other forms of acute organ injury.

News items for DRRX include detailed updates on the development of the company’s lead investigational drug candidate, larsucosterol. These releases cover milestones such as the Phase 2b AHFIRM trial results, publication of data in NEJM Evidence, presentations at major liver disease meetings, and plans for a registrational Phase 3 trial in severe AH. Company communications also highlight that larsucosterol has received Fast Track and Breakthrough Therapy designations from the U.S. Food and Drug Administration for the treatment of AH.

The feed also captures DURECT’s corporate and portfolio developments, including announcements about its FDA-approved non-opioid analgesic POSIMIR, based on the SABER platform technology, and the sale of the ALZET osmotic pump product line. In 2025, a significant portion of the news flow relates to the tender offer and merger under which a subsidiary of Bausch Health Americas, Inc. agreed to acquire all outstanding shares of DURECT, followed by completion of the merger and subsequent delisting and deregistration of DRRX.

Investors and researchers can use this page to review historical earnings releases, business updates, clinical trial communications and acquisition-related announcements that together document DURECT’s evolution from a publicly traded company to an indirect wholly owned subsidiary within a larger pharmaceutical group.